The DOI matches its Crossref record; 298 of the 298 references it cites were found in a registry or an index.
TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants – past, present and future
Open accessAbstract
Tumor Necrosis Factor (TNF), initially known for its tumor cytotoxicity, is a potent mediator of inflammation, as well as many normal physiological functions in homeostasis and health, and anti-microbial immunity. It also appears to have a central role in neurobiology, although this area of TNF biology is only recently emerging. Here, we review the basic biology of TNF and its normal effector functions, and discuss the advantages and disadvantages of therapeutic neutralization of TNF - now a commonplace practice in the treatment of a wide range of human inflammatory diseases. With over ten years of experience, and an emerging range of anti-TNF biologics now available, we also review their modes of action, which appear to be far more complex than had originally been anticipated. Finally, we highlight the current challenges for therapeutic intervention of TNF: (i) to discover and produce orally delivered small molecule TNF-inhibitors, (ii) to specifically target selected TNF producing cells or individual (diseased) tissue targets, and (iii) to pre-identify anti-TNF treatment responders. Although the future looks bright, the therapeutic modulation of TNF now moves into the era of personalized medicine with society's challenging expectations of durable treatment success and of achieving long-term disease remission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–298 of 298
Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis
Mirkov, M. U., Cui, J., Vermeulen, S. H. H. M., Stahl, E. A., Toonen, E. J. M., Makkinje, R. R., Lee, A. T., Huizinga, T. W. J., Allaart, R., Barton, A. C., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202405 · Cited by 112
Baert, F., Glorieus, E., Reenaers, C., D’Haens, G., Peeters, H., Franchimont, D., Dewit, O., Caenepeel, P., Louis, E. J., & Assche, G. V. (2012) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2012.03.018 · Cited by 111
PHARMACOLOGICAL PROPERTIES OF THALIDOMIDE (α‐PHTHALIMIDO GLUTARIMIDE), A NEW SEDATIVE HYPNOTIC DRUG
SOMERS, G. F. (1960) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1960.tb01217.x · Cited by 110
Demyelination and inhibition of tumor necrosis factor (TNF).
Magnano, M. D., Robinson, W. H., & Genovese, M. C. (2004) · PubMed · Cited by 107
Cantarini, L., Lucherini, O. M., Muscari, I., Frediani, B., Galeazzi, M., Brizi, M. G., Simonini, G., & Cimaz, R. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.07.020 · Cited by 106
Vaitla, P., Radford, P. M., Tighe, P. J., Powell, R. J., McDermott, E. M., Todd, I., & Drewe, E. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30215 · Cited by 103
TNF Receptor-Associated Factor 3 Is Required for T Cell-Mediated Immunity and TCR/CD28 Signaling
Xie, P., Kraus, Z., Stunz, L. L., Liu, Y., & Bishop, G. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000290 · Cited by 102
Lymphotoxin and TNF: How it all began—A tribute to the travelers
Ruddle, N. H. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.02.001 · Cited by 102
NFκB inhibitors: Strategies from poxviruses
Mohamed, M. R., & McFadden, G. (2009) · Cell Cycle · doi:10.4161/cc.8.19.9683 · Cited by 100
Thalidomide–A Notorious Sedative to a Wonder Anticancer Drug
Zhou, S. Y., Wang, F., Hsieh, T.-C., WU, J. M., & Wu, E. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990198 · Cited by 100
Rutgeerts, P., Lemmens, L., Assche, G. V., Noman, M., Borghini-Fuhrer, I., & Goedkoop, R. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01414.x · Cited by 98
Opposing Roles for TRAF1 in the Alternative versus Classical NF-κB Pathway in T Cells
McPherson, A. J., Snell, L. M., Mak, T. W., & Watts, T. H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.350538 · Cited by 98
Wong, G. H., Tartaglia, L. A., Lee, M. S., & Goeddel, D. V. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.10.3350 · Cited by 97
Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane).
Singh, S., & Aggarwal, B. B. (1995) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)45855-8 · Cited by 97
Montgomery, S. L., Mastrangelo, M. A., Habib, D., Narrow, W. C., Knowlden, S. A., Wright, T. W., & Bowers, W. J. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.07.001 · Cited by 96
Todd, I., Radford, P. M., Draper‐Morgan, K., McIntosh, R. S., Bainbridge, S., Dickinson, P., Jamhawi, L., Sansaridis, M., Huggins, M. L., Tighe, P. J., et al. (2004) · Immunology · doi:10.1111/j.1365-2567.2004.01942.x · Cited by 96
Schreiber, M., Sedger, L. M., & McFadden, G. (1997) · Journal of Virology · doi:10.1128/jvi.71.3.2171-2181.1997 · Cited by 95
Self-citationBrain Protection from Stroke with Intravenous TNF α Decoy Receptor-Trojan Horse Fusion Protein
Sumbria, R. K., Boado, R. J., & Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.97 · Cited by 95
Salemi, S., Diamanti, A. P., Germano, V., Donatelli, I., Martino, A. D., Facchini, M., Nisini, R., Biselli, R., Ferlito, C., Podestà, E., et al. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.09.014 · Cited by 94
Zhang, Y., Xu, J. Y., Levin, J. I., Hegen, M., Li, G., Robertshaw, H., Brennan, F. M., Cummons, T. A., Clarke, D., Vansell, N. R., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.059675 · Cited by 94
Qing, G., Qu, Z., & Xiao, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508776200 · Cited by 92
Kirchner, S., Holler, E., Haffner, S., Andreesen, R., & Eißner, G. (2004) · Cytokine · doi:10.1016/j.cyto.2004.06.008 · Cited by 91
Kobie, J. J., Zheng, B., Bryk, P., Barnes, M., Ritchlin, C. T., Tabechian, D., Anandarajah, A., Looney, R. J., Thiele, R., Anolik, J. H., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3542 · Cited by 91
Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response
Emery, P., & Dorner, T. E. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.148015 · Cited by 91
Edwards, C. K. (1999) · Annals of the Rheumatic Diseases · doi:10.1136/ard.58.2008.i73 · Cited by 90
Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors
Solomon, A. J., Spain, R., Kruer, M. C., & BOURDETTE, D. N. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511412996 · Cited by 90
Kelker, H. C., Oppenheim, J. D., Stone‐Wolff, D. S., Henriksen-DeStefano, D., Aggarwal, B. B., Stevenson, H. C., & Vilček, J. (1985) · International Journal of Cancer · doi:10.1002/ijc.2910360112 · Cited by 88
Curcumin Attenuates Diabetic Neuropathic Pain by Downregulating TNF-α in a Rat Model
Li, Y., Zhang, Y., Liu, D.-B., Liu, H., Hou, W., & Dong, Y. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.5224 · Cited by 88
Lawrance, I. C., Radford‐Smith, G. L., Bampton, P. A., Andrews, J. M., Tan, P. K., Croft, A. R., Gearry, R. B., & Florin, T. H. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06407.x · Cited by 86
Anti-TNF Treatment in Rheumatoid Arthritis
Geiler, J., Buch, M. H., & McDermott, M. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798157658 · Cited by 85
Self-citationZaremba, J., Skrobański, P., & Losy, J. (2001) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(01)00058-0 · Cited by 83
Dickie, L. J., Aziz, A., Savic, S., Lucherini, O. M., Cantarini, L., Geiler, J., Wong, C. H., Coughlan, R. J., Lane, T., Lachmann, H. J., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201197 · Cited by 81
Self-citationHe, P., Cheng, X., Staufenbiel, M., Li, R., & Shen, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055091 · Cited by 80
A PEGylated Fab′ Fragment against Tumor Necrosis Factor for the Treatment of Crohn Disease
Bourne, T., Fossati, G., & Nesbitt, A. M. (2008) · BioDrugs · doi:10.2165/00063030-200822050-00005 · Cited by 79
Schreiber, M., Rajarathnam, K., & McFadden, G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.23.13333 · Cited by 75
Zuckerman, S. H., Evans, G. F., & Guthrie, L. (1991) · PubMed · Cited by 74
Cardiovascular risk in rheumatoid arthritis: How to lower the risk?
der Stoep, D. F. V. B.-V., Klop, B., van Zeben, D., Hazes, J. M. W., & Cabezas, M. C. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.09.006 · Cited by 74
Falling into TRAPS – receptor misfolding in the TNF receptor 1-associated periodic fever syndrome
Kimberley, F. C., Lobito, A. A., Siegel, R. M., & Screaton, G. R. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2197 · Cited by 74
Zhang, H., Yan, D., Shi, X., Liang, H., Pang, Y., Qin, N., Chen, H., Wang, J., Yin, B., Jiang, X., et al. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0208078 · Cited by 74
Sode, J., Vogel, U. B., Bank, S., Andersen, P. S., Thomsen, M. K., Hetland, M. L., Locht, H., Heegaard, N. H. H., & Andersen, V. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100361 · Cited by 72
Savic, S., Dickie, L. J., Wittmann, M., & McDermott, M. (2012) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2012.07.009 · Cited by 70
Self-citationHiguchi, M., Nagasawa, K., Horiuchi, T., Oike, M., Ito, Y., Yasukawa, M., & Niho, Y. (1997) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1996.4291 · Cited by 70
Ma, L., Gong, H., Zhu, H., Ji, Q., Su, P., Liu, P., Cao, S., Yao, J., Jiang, L., Han, M., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.521708 · Cited by 70
Wong, A. K., Kerkoutian, S., SAID, J. W., Rashidi, H. H., & Pullarkat, S. T. (2011) · Clinical Rheumatology · doi:10.1007/s10067-011-1895-y · Cited by 68
Neuroprotection with a Brain-Penetrating Biologic Tumor Necrosis Factor Inhibitor
Zhou, Q.-H., Sumbria, R. K., Hui, E. K., Lu, J. Z., Boado, R. J., & Pardridge, W. M. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.185876 · Cited by 68
Perispinal etanercept: a new therapeutic paradigm in neurology
Tobinick, E. L. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.52 · Cited by 66
Sockolosky, J. T., Tiffany, M. R., & Szoka, F. C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208857109 · Cited by 64
Schreiber, M., & McFadden, G. (1994) · Virology · doi:10.1006/viro.1994.1585 · Cited by 64
Krintel, S. B., Palermo, G., Johansen, J. S., Germer, S., Essioux, L., Benayed, R., Badi, L., Østergaard, M., & Hetland, M. L. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283544043 · Cited by 63
Caspase‐8 and caspase‐10 activate NF‐κB through RIP, NIK and IKKα kinases
Shikama, Y., Yamada, M., & Miyashita, T. (2003) · European Journal of Immunology · doi:10.1002/eji.200324013 · Cited by 62
Etanercept – TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers?
Marotte, H., & Cimaz, R. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.896334 · Cited by 62
Role of SODD in Regulation of Tumor Necrosis Factor Responses
Takada, H., Chen, N., Mirtsos, C., Suzuki, S., Suzuki, N., Wakeham, A. C., Mak, T. W., & Yeh, W. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.11.4026-4033.2003 · Cited by 62
Focal cerebral ischemia in the TNFalpha-transgenic rat
Pettigrew, L. C., Kindy, M. S., Scheff, S. W., Springer, J. E., Kryscio, R. J., Li, Y., & Grass, D. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-47 · Cited by 61
Peppelenbosch, M. P., Boone, E., Jones, G. E., van Deventer, S. J. H., Haegeman, G., Fiers, W., Grooten, J., & Ridley, A. J. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.2.837 · Cited by 60
TNFα reverse signaling promotes sympathetic axon growth and target innervation
Kisiswa, L., Osório, C., Erice, C., Vizard, T. N., Wyatt, S. L., & Davies, A. M. (2013) · Nature Neuroscience · doi:10.1038/nn.3430 · Cited by 60
Advances in the treatment of rheumatoid arthritis
Vivar, N., & van Vollenhoven, R. (2014) · F1000Prime Reports · doi:10.12703/p6-31 · Cited by 59
Vincent, K. J., & Zurini, M. G. M. (2012) · Biotechnology Journal · doi:10.1002/biot.201200250 · Cited by 57
Matsuda, I., Matsuo, K., Matsushita, Y., Haruna, Y., Niwa, M., & Kataoka, T. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.506485 · Cited by 56
Rheumatoid arthritis and cardiovascular disease: an update on treatment issues
Barbhaiya, M., & Solomon, D. H. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32835fd7f8 · Cited by 56
Cooper, D. L., Martin, S. G., Robinson, J. I., Mackie, S. L., Charles, C. J., Nam, J. L., Isaacs, J. D., Emery, P., & Morgan, A. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0028918 · Cited by 55
Zhong, Y., Liu, T., & Guo, Z. (2011) · Inflammation Research · doi:10.1007/s00011-011-0389-3 · Cited by 55
Palombella, V. J., Mendelsohn, J. M., & Vilček, J. (1988) · Journal of Cellular Physiology · doi:10.1002/jcp.1041350104 · Cited by 53
Beck, G., Bottomley, G. A., Bradshaw, D. J., et al. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.302.1.390 · Cited by 52
Majumder, S., Sridhara, S. R. C., Banerjee, S., & Chatterjee, S. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612801784443 · Cited by 52
Mana, F. (2013) · Journal of Crohns & Colitis · Cited by 52
Sumbria, R. K., Zhou, Q.-H., Hui, E. K., Lu, J. Z., Boado, R. J., & Pardridge, W. M. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400004a · Cited by 51
Lucherini, O. M., Obici, L. P., Ferracin, M., Fulci, V., McDermott, M., Merlini, G., Muscari, I., Magnotti, F., Dickie, L. J., Galeazzi, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073443 · Cited by 47
Self-citationMoreland, L. W., McCabe, D., Caldwell, J. R., Sack, M. R., Weisman, M. H., Henry, G., Seely, J. E., Martin, S. W., Yee, C. L., Bendele, A. M., et al. (2000) · PubMed · Cited by 44
Feagan, B. G., Sandborn, W. J., Lichtenstein, G. R., Radford‐Smith, G. L., PATEL, J., & Innes, A. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02791.x · Cited by 44
Xin, L., Wang, J., Zhang, H., et al. (2006) · International Journal of Molecular Medicine · doi:10.3892/ijmm.18.5.885 · Cited by 40
Oldfield, V., & Plosker, G. L. (2009) · BioDrugs · doi:10.2165/00063030-200923020-00005 · Cited by 40
Stamou, P., & Kontoyiannis, D. L. (2010) · Current directions in autoimmunity · doi:10.1159/000289197 · Cited by 38
Murine Tumor Necrosis-Inducing Factor: Purification and Effects on Myelomonocytic Leukemia Cells 2 3
Green, S., Dobrjansky, A., & Chiasson, M. A. (1982) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/68.6.997 · Cited by 38
Infliximab Induces Clonal Expansion of γδ-T Cells in Crohn's Disease: A Predictor of Lymphoma Risk?
Kelsen, J., Dige, A. K., Schwindt, H., d’Amore, F., Pedersen, F. S., Agnholt, J. S., Christensen, L. A., Dahlerup, J. F., & Hvas, C. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017890 · Cited by 37
Márquez, A., Ferreiro-Iglesias, A., Dávila-Fajardo, C. L., Montes, A., Pascual‐Salcedo, D., Pérez-Pampín, E. M., Ramos, M. J. M., García-Portales, R., Navarro, F., Moreira, V., et al. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4504 · Cited by 36
Focal cerebral ischemia and mitochondrial dysfunction in the TNFα-transgenic rat
Pandya, J. D., Sullivan, P. G., & Pettigrew, L. C. (2011) · Brain Research · doi:10.1016/j.brainres.2011.01.102 · Cited by 34
Feagan, B. G., Sandborn, W. J., Baker, J. P., Cominelli, F., Sutherland, L. R., Elson, C. O., Salzberg, B. A., Archambault, A., Bernstein, C. N., Lichtenstein, G. R., et al. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02336.x · Cited by 34
Molnár, T., Farkas, K., Nyári, T., Szepes, Z., Nagy, F. T., & Wittmann, T. (2012) · PubMed · Cited by 34
Tresch, S., Trüeb, R. M., Kamarachev, J., French, L. E., & Hofbauer, G. F. L. (2009) · Dermatology · doi:10.1159/000232389 · Cited by 32
Ma, C. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i21.3347 · Cited by 31
M‐T2: A poxvirus TNF receptor homologue with dual activities
Sedger, L. M., & McFadden, G. (1996) · Immunology and Cell Biology · doi:10.1038/icb.1996.87 · Cited by 29
Self-citationCao, J., Meng, F., Gao, X., Dong, H., & Yao, W. (2011) · The Protein Journal · doi:10.1007/s10930-011-9330-4 · Cited by 28
Involvement of TNF-α in glutamate-induced apoptosis in a differentiated neuronal cell line
Kogo, J., Takeba, Y., Kumai, T., Kitaoka, Y., Matsumoto, N., Ueno, S., & Kobayashi, S. (2006) · Brain Research · doi:10.1016/j.brainres.2006.09.006 · Cited by 26
Wang, A. Y. L., Chou, F., Chen, S., Lin, S., Chang, D., & Sytwu, H. (2011) · Journal of Autoimmunity · doi:10.1016/j.jaut.2011.05.013 · Cited by 26
TNF-αPolymorphisms in Juvenile Idiopathic Arthritis: Which Potential Clinical Implications?
Scardapane, A., Breda, L., Lucantoni, M., & Chiarelli, F. (2012) · International Journal of Rheumatology · doi:10.1155/2012/756291 · Cited by 25
Hayder, H., Blanden, R. V., Körner, H., Riminton, S., Sedgwick, J. D., & Müllbacher, A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1516 · Cited by 23
Michel, M., Wilhelmi, I., Schultz, A.-S., Preußner, M., & Heyd, F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.526269 · Cited by 23
ZHONG, Y., Yu, W., Feng, J., Fan, Z., & Li, J. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.1647 · Cited by 23
Trinchard-Lugan, I., Ho-Nguyen, Q., Bilham, W. M., Buraglio, M., Ythier, A., & Munafo, A. (2001) · PubMed · Cited by 22
Andrade, P., Visser-Vandewalle, V. E. R. M., Rosario, J. S. D., Daemen, M. A. R. C., Buurman, W. A., Steinbusch, H. W. M., & Hoogland, G. (2012) · Brain Research · doi:10.1016/j.brainres.2012.02.033 · Cited by 20
CDP571, a Humanized Anti-Tumor Necrosis Factor-α Monoclonal Antibody in Pediatric Crohn’s Disease
Mamula, P., Cohen, S. A., Ferry, G. D., Kirschner, B. S., Winter, H. S., Innes, A., Patel, J., & Baldassano, R. N. (2004) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200411000-00005 · Cited by 19
Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease
Ahmad, N. M., Ahmad, K. M., & Younus, F. (2006) · Journal of Infection · doi:10.1016/j.jinf.2006.03.025 · Cited by 17
Kuprash, D. V., Qin, Z., Ito, D., Grivennikov, S. I., Abe, K., Drutskaya, L. N., Blankenstein, T. J. F., & Nedospasov, S. A. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.023 · Cited by 13
Dejaco, C., Duftner, C., Klotz, W., Schirmer, M., & Herold, M. (2009) · Rheumatology International · doi:10.1007/s00296-009-0978-4 · Cited by 10
An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-D.
Lacy, B. E., Chey, W. D., & Chang, L. (2013) · Europe PMC (PubMed Central) · Cited by 9
Population Pharmacokinetics of Onercept in Healthy Subjects
Glatt, S., Fuseau, E., Buraglio, M., & Nguyen, Q. T. X. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544120-00008 · Cited by 4
Serratrice, J., Serratrice, J., DISDIER, P., Dodé, C., & Weiller, P. (2006) · Clinical Rheumatology · doi:10.1007/s10067-006-0418-8 · Cited by 4
Komuro (2001) · doi:10.1002/1529-0131(200112)44:12
Research works printed but not linked: 65
- Matthews, 1980, Tumour-necrosis factor from the rabbit. IV. Purification and chemical characterization, Br J Cancer, 42, 416, 10.1038/bjc.1980.253 · doi:10.1038/bjc.1980.253
- Matthews, 1979, Tumour-necrosis factor from the rabbit. III. Relationship to interferons, Br J Cancer, 40, 534, 10.1038/bjc.1979.218 · doi:10.1038/bjc.1979.218
- Prince, 1982, Inhibition of L-cell growth in agarose (ILGA): a simple inexpensive method for the detection and quantitation of factors inhibiting tumor cell growth, J Immunol Methods, 48, 367, 10.1016/0022-1759(82)90337-4 · doi:10.1016/0022-1759(82)90337-4
- Bloksma, 1983, Antitumour activity of endotoxin, concanavalin A and poly I: C and their ability to elicit tumour necrosis factor, cytostatic factors, and interferon in vivo, Cancer Immunol Immunother, 16, 35, 10.1007/BF00199903 · doi:10.1007/bf00199903
- English, 1991, Differential regulation of lymphotoxin and tumor necrosis factor genes in human T lymphocytes, J Biol Chem, 266, 7108, 10.1016/S0021-9258(20)89617-3 · doi:10.1016/s0021-9258(20)89617-3
- Turner, 1988, Comparison of patterns of expression of tumour necrosis factor, lymphotoxin and interleukin-6 mRNA, Biochem Biophys Res Commun, 153, 1144, 10.1016/S0006-291X(88)81347-0 · doi:10.1016/s0006-291x(88)81347-0
- Ziegler-Heitbrock, 1986, Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity, Cancer Res, 46, 5947
- Haranaka, 1987, Antitumour effects of tumour necrosis factor: cytotoxic or necrotizing activity and its mechanism, Ciba Found Symp, 131, 140
- Schwartz, 1989, A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy, Biotherapy, 1, 207, 10.1007/BF02170889 · doi:10.1007/bf02170889
- Zamkoff, 1989, A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy, J Biol Response Mod, 8, 539
- Negrier, 1991, Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer, J Immunother, 11, 93, 10.1097/00002371-199202000-00003 · doi:10.1097/00002371-199202000-00003
- Xin, 2006, Dual regulation of soluble tumor necrosis factor-alpha induced activation of human monocytic cells via modulating transmembrane TNF-alpha-mediated ‘reverse signaling’, Int J Mol Med, 18, 885
- Austgulen, 1986, Role of monocyte cytotoxic factor in cytolysis of actinomycin D-treated WEHI 164 cells mediated by freshly isolated human adherent mononuclear blood cells, Cancer Res, 46, 4566
- Munker, 1987, In vitro action of tumor necrosis factor on myeloid leukemia cells, Blood, 69, 1102, 10.1182/blood.V69.4.1102.1102 · doi:10.1182/blood.v69.4.1102.1102
- Suyama, 1985, Effects of murine tumor necrosis factor on friend erythroleukemic cells, Exp Cell Biol, 53, 85
- Sedger, 2005, Viral inhibition of tumour necrosis factor-α and TNFα and TNF-receptor induced apoptosis and inflammation, Curr Med Chem Anti Inflam Anti Aller, 4, 597, 10.2174/156801405774933124 · doi:10.2174/156801405774933124
- Warzocha, 1995, Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system, Eur Cytokine Netw, 6, 83
- Fiers, 1987, Structure-function relationship of tumour necrosis factor and its mechanism of action, Ciba Found Symp, 131, 109
- Boecke, 2012, Factor associated with neutral sphingomyelinase activity mediates navigational capacity of leukocytes responding to wounds and infection: live imaging studies in zebrafish larvae, J Immunol, 189, 1559, 10.4049/jimmunol.1102207 · DOI
- Christoforidis, 2003, Isolated limb perfusion: distinct tourniquet and tumor necrosis factor effects on the early hemodynamic response, Arch Surg, 138, 17, 10.1001/archsurg.138.1.17 · doi:10.1001/archsurg.138.1.17
- Yousaf, 2005, Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-κB activation, Arthritis Rheum, 52, 2906, 10.1002/art.21268 · DOI
- Upton, 1991, Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence, Virology, 184, 370, 10.1016/0042-6822(91)90853-4 · doi:10.1016/0042-6822(91)90853-4
- Hutas, 2010, Golimumab as the first monthly subcutaneous fully human anti-TNF-α antibody in the treatment of inflammatory arthropathies, Immunotherapy, 2, 453, 10.2217/imt.10.34 · doi:10.2217/imt.10.34
- Meroni, 2014, Tumour necrosis factor-α antagonists in the treatment of Rheumatoid arthritis: an immunological perspective, BioDrugs, 28, S5, 10.1007/s40259-013-0063-0 · DOI
- Bendele, 1999, Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats, Clin Exp Rheumatol, 17, 553
- McComb, 1999, Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: correlation of plasma levels with efficacy, J Rheumatol, 26, 1347
- Trinchard-Lugan, 2001, Safety, pharmakinetics and pharmacodynamics of recombinant human tumour necrosis factor binding proteins-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers, Eur Cytokine Netw, 12, 391
- Kay, 2013, Biosimilars to treat inflammatory arthritis: the challenge of proving identity, Ann Rheum Dis, 72, 1589, 10.1136/annrheumdis-2012-203198 · doi:10.1136/annrheumdis-2012-203198
- Scheinberg, 2012, The advent of biosimilar therapies in rheumatology-“O brave new world”, Nat Rev Rheumatol, 8, 430, 10.1038/nrrheum.2012.84 · doi:10.1038/nrrheum.2012.84
- Leck, 1962, Incidence of malformations since the introduction of thalidomide, Br Med J, 2, 16, 10.1136/bmj.2.5296.16 · doi:10.1136/bmj.2.5296.16
- Ringheanu, 2004, Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease, Inflamm Bowel Dis, 10, 801, 10.1097/00054725-200411000-00015 · doi:10.1097/00054725-200411000-00015
- Xin, 2006, Dual regulation of soluble tumour necrosis factor-α inducing activation of human monocytic cells via modulation transmembrane TNFα-metiated “reverse signalling”, Int J Mol Med, 18, 885
- Mitoma, 2005, Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α, Gastroenterology, 128, 376, 10.1053/j.gastro.2004.11.060 · DOI · Paper page
- Nestorov, 2005, Clinical pharmacokinetics of TNF antagonists: how do they differ?, Semin Arthritis Rheum, 34, 12, 10.1016/j.semarthrit.2005.01.004 · doi:10.1016/j.semarthrit.2005.01.004
- Steenholdt, 2012, Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease, J Crohns Colitis, 6, 108, 10.1016/j.crohns.2011.08.001 · DOI
- Bracaglia, 2012, Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age, J Rheumatol, 39, 1287, 10.3899/jrheum.111555 · doi:10.3899/jrheum.111555
- Li Gobbi, 2005, Pneumonitis caused by Legionella pneumoniae in a patient with rheumatoid arthritis treated with anti-TNF-alpha therapy (infliximab), J Clin Rheumatol, 11, 119, 10.1097/01.rhu.0000158527.20518.30 · doi:10.1097/01.rhu.0000158527.20518.30
- Mancini, 2007, Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor-α (anti-TNF-alpha) treatment, Clin Microbiol Infect, 13, 1036, 10.1111/j.1469-0691.2007.01796.x · doi:10.1111/j.1469-0691.2007.01796.x
- Lanternier, 2013, Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study, Chest, 144, 990, 10.1378/chest.12-2820 · doi:10.1378/chest.12-2820
- Hofmann, 2009, Fulminant legionellosis in two patients treated with infliximab for Crohn's disease: case series and literature review, Can J Gastroenterol, 23, 829, 10.1155/2009/836938 · doi:10.1155/2009/836938
- Kang, 2007, Adenoviral pneumonia during etanercept treatment in a patient with rheumatoid arthritis, Korean J Intern Med, 22, 63, 10.3904/kjim.2007.22.1.63 · doi:10.3904/kjim.2007.22.1.63
- Smith, 2002, Viral pneumonia as a serious complication of etanercept therapy, Ann Intern Med, 136, 174, 10.7326/0003-4819-136-2-200201150-00020 · doi:10.7326/0003-4819-136-2-200201150-00020
- Cantini, 2014, Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance, J Rheumatol Suppl, 91, 47, 10.3899/jrheum.140102 · doi:10.3899/jrheum.140102
- Navarra, 2014, Risk of tuberculosis with anti-tumour necrosis factor-α therapy: substantially higher number of patients at risk in Asia, Int J Rheum Dis, 17, 3, 10.1111/1756-185X.12188 · doi:10.1111/1756-185x.12188
- Glenn, 2012, Epstein–Barr virus, human papillomavirus and mouse mammary tumour virus as multiple viruses in breast cancer, PLoS One, 7, e48788, 10.1371/journal.pone.0048788 · doi:10.1371/journal.pone.0048788
- Mohan, 2001, Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides, Arthritis Rheum, 44, 2862, 10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W · doi:10.1002/1529-0131(200112)44:12<2862::aid-art474>3.0.co;2-w
- Tanno, 2006, New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients, Clin Rheumatol, 25, 929, 10.1007/s10067-005-0097-x · doi:10.1007/s10067-005-0097-x
- Andreadou, 2013, Demyelinating disease following anti-TNFα treatment: a causal or coincidental association? Report of four cases and review of the literature, Case Rep Neurol Med, 2013, 671935
- Kaltsonoudis, 2014, Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study, Arthritis Res Ther, 16, R125, 10.1186/ar4582 · doi:10.1186/ar4582
- Ledingham, 2005, British thoracic society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments, Rheumatology (Oxford), 44, 1205, 10.1093/rheumatology/kei103 · doi:10.1093/rheumatology/kei103
- Lv, 2014, The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis: a meta-analysis, PLoS One, 9, e89422, 10.1371/journal.pone.0089442 · doi:10.1371/journal.pone.0089442
- Coulthard, 2013, Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients, Clin Exp Immunol, 170, 36, 10.1111/j.1365-2249.2012.04626.x · doi:10.1111/j.1365-2249.2012.04626.x
- Sandborn, 2013, A special meeting review edition: clinical research highlights in ibd: diagnosis and anti-tumor necrosis factor monitoring, Gastroenterol Hepatol, 9, 1
- Thomas, 2014, Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease, World J Gastroenterol, 20, 3609, 10.3748/wjg.v20.i13.3609 · doi:10.3748/wjg.v20.i13.3609
- Coulthard, 2011, Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients, Ann Rheum Dis, 70, 98, 10.1136/ard.2010.133249 · doi:10.1136/ard.2010.133249
- Sedger, 2006, Poxviral tumour necrosis factor receptor (TNFR)-like T2 proteins contain a concerved pre-ligand association domain (PLAD) that inhibits cellular TNFR2 induced cell death, J Virol, 80, 9300, 10.1128/JVI.02449-05 · DOI
- Macen, 1996, Expression of the myxoma virus tumor necrosis factor receptor homologue and M11L genes is required to prevent virus-induced apoptosis in infected rabbit T lymphocytes, Virology, 218, 232, 10.1006/viro.1996.0183 · doi:10.1006/viro.1996.0183
- Coulthard, 2012, Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients, Clin Exp Immunol, 170, 36, 10.1111/j.1365-2249.2012.04626.x · doi:10.1111/j.1365-2249.2012.04626.x
- Tobinick, 2010, Perispinal etanercept: a new therapeutic paradigm in neurology, Expert Rev Neurother, 10, 985, 10.1586/ern.10.52 · DOI
- Schabert, 2013, Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population, J Manag Care Pharm, 19, 621, 10.18553/jmcp.2013.19.8.621 · doi:10.18553/jmcp.2013.19.8.621
- Grover, 2012, Pharmaceutical companies and global lack of access to medicines: strengthening accountability under the right to health, J Law Med Ethics, 40, 234, 10.1111/j.1748-720X.2012.00661.x · doi:10.1111/j.1748-720x.2012.00661.x
- Deighton, 2010, BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy, Rheumatology (Oxford), 49, 1197, 10.1093/rheumatology/keq006a · doi:10.1093/rheumatology/keq006a
- Scott, 2009, NICE guidelines on anti-tumor necrosis factor therapy for RA, Nat Clin Pract Rheumatol, 5, 16, 10.1038/ncprheum0964 · doi:10.1038/ncprheum0964
- Nikas, 2003, Onercept. Serono., Curr Opin Investig Drugs, 4, 1369
- Davis, 2000, Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update, Ann Rheum Dis, 59, 41, 10.1136/ard.59.suppl_1.i41 · doi:10.1136/ard.59.suppl_1.i41
Cited by
Jang, D.-I., Lee, A.-H., Shin, H.-Y., Song, H.-R., Park, J.-H., Kang, T.-B., Lee, S.-R., & Yang, S.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052719 · Cited by 1,694
The Semantics of Microglia Activation: Neuroinflammation, Homeostasis, and Stress
Woodburn, S. C., Bollinger, J. L., & Wohleb, E. S. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02309-6 · Cited by 783
Necroptosis: a regulated inflammatory mode of cell death
Dhuriya, Y. K., & Sharma, D. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1235-0 · Cited by 718
Particulate Matter Air Pollution: Effects on the Cardiovascular System
Hamanaka, R. B., & Mutlu, G. M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00680 · Cited by 654
The role of IL-1β and TNF-α in intervertebral disc degeneration
Wang, Y., Che, M., Xin, J., Zheng, Z., Li, J., & Zhang, S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110660 · Cited by 627
Metadata
- Authors
- Sedger, L. M., & McDermott, M. F.
- Venue
- Cytokine & Growth Factor Reviews
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 25
- Issue
- 4
- Pages
- 453-472
- ISSN
- 1359-6101 (ISSN-L)
- OpenAlex
- W1964249139
- Cited by
- 771
- References
- 298
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/3.0/ (vor, 17 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.